Acta Diabetologica (2018) 55:341–353
The eects of resveratrol on markers of oxidative stress in patients
with type 2 diabetes: a randomized, double‑blind, placebo‑controlled
· Hadi Khodabandehloo
· Ensieh Nasli Esfahani
· Reza Meshkani
Received: 15 November 2017 / Accepted: 29 December 2017 / Published online: 22 January 2018
© Springer-Verlag Italia S.r.l., part of Springer Nature 2018
Aims Oxidative stress plays a pivotal role in the pathogenesis of type 2 diabetes (T2D). In vitro and animal studies have
shown that resveratrol exerts an antioxidant eﬀect, but clinical trials addressing this eﬀect in patients with T2D are limited.
The aim of this study was to determine whether resveratrol supplementation aﬀects oxidative stress markers in a randomized,
placebo-controlled, double-blind clinical trial.
Methods A total of 48 patients with T2D randomly were assigned to receive 800 mg/day resveratrol or placebo for 2 months.
Plasma total antioxidant capacity, malondialdehyde concentration, protein carbonyl and total thiol contents, intracellular
superoxide anion (O
·) and hydrogen peroxide (H
) in PBMCs, the expression of genes involved in oxidative stress
responses (Nrf2, SOD, Cat, HO-1, RAGE, NOS) in PBMCs, and metabolic and anthropometric parameters were measured
at the baseline and at the trial end.
Results Compared with the placebo group, resveratrol reduced plasma protein carbonyl content and PBMCs O
· level and
signiﬁcantly increased plasma total antioxidant capacity and total thiol content. Furthermore, the expression of Nrf2 and
SOD was signiﬁcantly increased after resveratrol consumption. Resveratrol had no signiﬁcant eﬀects on the metabolic and
anthropometric parameters except for a signiﬁcant reduction in weight, BMI, and blood pressure levels. Resveratrol was well
tolerated, and no serious adverse event was occurred.
Conclusions Our study demonstrated that 8 weeks of supplementation with 800 mg/day resveratrol has an antioxidant eﬀect
in the blood and PBMCs of patients with T2D.
Clinical Trial Registry number and website IRCT registration number: IRCT2015072523336N1 and http ://en.sear ch.irct .ir/
view /2475 2.
Keywords Oxidative stress · Type 2 diabetes · Resveratrol · PBMC · Clinical trial · Nrf2 · ROS
BMI Body mass index
DCFH-DA Dichloro-dihydro-ﬂuorescein diacetate
FBS Fasting blood sugar
FRAP Ferric reducing ability of plasma
Managed by Massimo Porta.
Electronic supplementary material The online version of this
article (http s://doi.org/10.1007 /s005 92-017-1098 -3) contains
supplementary material, which is available to authorized users.
* Reza Meshkani
Department of Biochemistry, Faculty of Medicine,
Tehran University of Medical Sciences, Tehran,
Islamic Republic of Iran
Diabetes Research Center, Endocrinology and Metabolism
Clinical Sciences Institute, Tehran University of Medical
Sciences, Tehran, Islamic Republic of Iran
Endocrinology and Metabolism Research Center,
Endocrinology and Metabolism Clinical Sciences
Institute, Tehran University of Medical Sciences, Tehran,
Islamic Republic of Iran